{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-005535","form_type":"8-K","ticker":"ELVN","cik":"0001672619","company_name":"Enliven Therapeutics, Inc.","filed_at":"2026-01-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.843890+00:00","generated_at":"2026-05-16T11:22:47.243705+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Enliven Therapeutics appoints Scott Garland to board; Phillips resigns as ELVN prepares for Phase 3","bullets":["Scott Garland appointed as Class I director and Chair of Nominating and Corporate Governance Committee effective Jan 7, 2026.","Garland receives $40k annual cash (director) + $10k (committee chair) and initial stock option grant with ~$650k fair value vesting over 3 years.","Andrew Phillips resigned from board and committees effective Jan 7, 2026; resignation not due to any disagreement with company.","Garland brings biopharma commercial expertise as company advances ELVN-001 toward Phase 3 pivotal trial in CML in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-005535","json":"https://secwatch.observer/filing/0001193125-26-005535.json","markdown":"https://secwatch.observer/filing/0001193125-26-005535.md","text":"https://secwatch.observer/filing/0001193125-26-005535.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526005535/0001193125-26-005535-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672619/000119312526005535/d28332d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:22:47.243705+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}